Health care executives most highly compensated

On average, CEOs for HMOs and other health care companies receive two thirds more compensation than their counterparts in other industries, according to the Crystal Report on Executive Compensation. In studying compensation packages for over 1,500 CEOs, Crystal found that the people at the top of HMOs and health care companies live better than CEOs in the consumer, pharmaceutical, and finance industries.

Crystal put each CEO into an industry category; 31 categories had sufficient data to allow industry-to-industry comparisons of executive compensation packages, after adjusting for company size and shareholder-return performance. From these 31 industries, a baseline was developed. The average adjusted compensation for all CEOs in an industry was then compared with the baseline.

How chiefs in various industries compare to baseline

On average, CEOs in six industries receive compensation at least 25 percent below Crystal’s baseline. CEOs in four industries receive at least 25 percent more.

SOURCE: CRYSTAL REPORT ON EXECUTIVE COMPENSATION, DECEMBER 1998

Meetings

Home Care Leadership Summit Atlanta, GA November 17–18, 2014
Customer Analytics & Engagement in Health Insurance Chicago December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference Alexandria, VA December 4–5, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference Boston December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference San Diego December 5, 2014
8th Annual Medical Device Clinical Trials Conference Chicago December 8–9, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for October 2014

FEATURES

The Clinical Trial Model Is Up for Review

Pyrazinamide-Induced Hyperuricemia

Lung Cancer Research Is Taking On New Challenges

Medical Applications for 3D Printing: Current and Projected Uses

PIPELINE PLUS

Steady Progress on Parkinson’s Disease

DEPARTMENTS

MEDICATION ERRORS

Telling True Stories Is an ISMP Hallmark

PRESCRIPTION: WASHINGTON

FDA Accepts Its First Biosimilar Application

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

DRUG FORECAST

Edoxaban: an Investigational Factor Xa Inhibitor


Our most popular topics on Managedcaremag.com